Clinical trials with Astegolimab

  • CT-EU-00057072

    Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    • Astegolimab
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    • Astegolimab
  • Long-term astegolimab safety for people with obstructive pulmonary disease

    This study is checking how safe a medicine called astegolimab is when used for a long time by people with a lung condition known as chronic obstructive pulmonary disease (COPD). It’s the third part (phase III) of the research, which means it’s built on past studies. This study is open-label, which means everyone knows they’re getting astegolimab. It’s only for people who’ve already finished a year in other studies (GB43311 or GB44332) where they might have got a placebo. They want to see if there are any problems that arise from using astegolimab for a long time.

    • Astegolimab